TARO News and Press, Taro Pharmaceutical Industries Ltd. From 10/25/19

Earnings Call to Discuss Results to be Conducted Tuesday, November 5 at 8:00 am ET Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for quarter and six months ended September 30, 2019, on Monday, November 4, 2019. The C...

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...

Aclaris Therapeutics (NASDAQ: ACRS ) together with Allergan has filed a patent infringement lawsuit against Taro Pharmaceuticals (NYSE: TARO ) in Delaware court, related to an ANDA filed by Taro to market a generic version of RHOFADE (oxymetazoline hydrochloride) cream, 1%. More new...

After losing more than 77% of its total enterprise value in less than four years, Akorn, Inc. ( AKRX ) is a name to be followed carefully. The most significant risk is the company’s financial debt, which does not justify the current low valuation. Besides, Akorn recently announced tha...

Taro Pharmaceutical (NYSE: TARO ): Q1 GAAP EPS of $1.72 misses by $0.24 . More news on: Taro Pharmaceutical Industries Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2019. Quarter ended June 30, 2019 Highlights - compared to June 30, 2018 Net sales of $161.3 million, in...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2019, after the close of market on Thursday August 8, 2019. The release will be accessible on Taro’s website at www.taro.com . About ...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2019, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Ta...

Introduction Taro Pharmaceuticals ( TARO ) is an generic pharmaceutical company achieving over $600+ million in sales in FY2018 stemming from organic volume growth. The company has an unique structure, being located in Israel but is 85% owned by Indian generic company Sun Pharmaceuticals a...

The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts ...